Myasthenia Gravis: Disease Biology and Autoantibody Targets

Myasthenia gravis (MG) is an autoimmune neuromuscular disease driven by pathogenic autoantibodies — predominantly anti-AChR (acetylcholine receptor) and anti-MuSK (muscle-specific kinase) — that impair neuromuscular junction transmission. These autoantibodies are the central pathogenic mediators of the disease, and understanding their distinct mechanisms of harm is foundational to evaluating why multiple therapeutic classes have emerged as rational treatment strategies.

In anti-AChR MG — the most common serological subtype — pathogenic IgG antibodies bind to acetylcholine receptors at the postsynaptic membrane of the neuromuscular junction. This binding triggers complement activation, accelerates receptor degradation, and blocks acetylcholine binding, collectively impairing the signal transmission required for voluntary muscle contraction. The complement cascade, particularly the terminal pathway culminating in the membrane attack complex (MAC), is a primary effector of receptor destruction in anti-AChR MG.

Anti-MuSK MG presents a distinct pathophysiology. MuSK antibodies are predominantly IgG4 subclass and do not activate complement; instead, they disrupt the clustering of AChRs at the neuromuscular junction by interfering with MuSK’s role in receptor aggregation. This mechanistic distinction has important therapeutic implications — complement inhibitors are less likely to be effective in anti-MuSK MG, whereas FcRn antagonists that broadly reduce IgG levels may offer benefit across both serological subtypes.

The neuromuscular junction is therefore the convergent site of autoantibody-mediated damage in MG, regardless of serological subtype. Therapeutic strategies targeting different nodes in this pathogenic cascade — upstream autoantibody depletion via FcRn antagonism, or downstream complement blockade — reflect the complexity of the disease biology and the rationale for multiple mechanistic approaches competing in the same clinical space. According to WHO and global rare disease registries, MG affects an estimated 14–20 per 100,000 people worldwide, underscoring the commercial and clinical significance of the rapidly expanding treatment pipeline.

Two Mechanistic Approaches: Complement Inhibition vs. FcRn Antagonism

The two principal mechanistic classes advancing in MG — C5 complement inhibitors and neonatal Fc receptor (FcRn) antagonists — act at distinct points in the autoimmune cascade, and their differentiation has direct implications for patient selection, trial design, and competitive positioning.

C5 complement inhibitors block the terminal complement cascade by targeting the C5 protein, preventing cleavage into C5a and C5b. C5b is the initiating component of the membrane attack complex (MAC), which directly lyses cell membranes — including the postsynaptic membrane of the neuromuscular junction. By preventing MAC formation, C5 inhibitors interrupt the complement-mediated destruction of AChRs that is central to anti-AChR MG pathology. This mechanism is well-validated in the complement inhibitor class: eculizumab, the first-generation C5 inhibitor developed by Alexion (now part of AstraZeneca), established proof-of-concept for complement blockade in MG, and ravulizumab — its long-acting successor — was designed to extend dosing intervals while maintaining equivalent C5 inhibition.

FcRn antagonists operate through a fundamentally different and upstream mechanism. The neonatal Fc receptor (FcRn) is responsible for recycling IgG antibodies back into circulation, extending their half-life. By blocking FcRn, agents such as efgartigimod (argenx) accelerate IgG catabolism, reducing total circulating IgG — including the pathogenic anti-AChR and anti-MuSK autoantibodies responsible for MG. Because the mechanism is antibody-class-wide rather than antigen-specific, FcRn antagonists can theoretically benefit patients across serological subtypes, including anti-MuSK MG where complement-mediated damage is not a primary driver.

“The myasthenia gravis therapeutic landscape has undergone rapid evolution with the approval of complement inhibitors and neonatal Fc receptor (FcRn) antagonists — and new entrants including AstraZeneca’s C5 complement inhibitor gefurulimab are now advancing into late-stage clinical development.”

The practical consequence of this mechanistic divergence is that C5 complement inhibitors and FcRn antagonists are not straightforwardly interchangeable. Complement inhibitors are most rationally applied in anti-AChR MG where complement activation is a documented effector mechanism. FcRn antagonists carry a broader serological remit but also a broader immunosuppressive footprint — reducing all circulating IgG, not just pathogenic autoantibodies. These trade-offs will shape how physicians, payers, and clinical trialists position gefurulimab relative to the existing approved agents. According to FDA guidance on rare autoimmune disease trials, patient stratification by autoantibody subtype is increasingly considered a key element of trial design and regulatory review.

The Competitive Landscape: Gefurulimab, Ravulizumab, and Efgartigimod

The myasthenia gravis competitive landscape now spans multiple mechanistic classes, with AstraZeneca, argenx, and Alexion/AstraZeneca all fielding late-stage assets. Understanding the positioning of gefurulimab requires situating it within this crowded field.

Ravulizumab, developed by Alexion (now part of AstraZeneca), is a long-acting C5 complement inhibitor that shares its primary molecular target — the C5 complement protein — with gefurulimab. Ravulizumab was engineered from eculizumab through modifications that extend its half-life and enable less frequent dosing. Both ravulizumab and gefurulimab therefore compete not only with agents from rival companies but, in a sense, with each other within AstraZeneca’s own portfolio — a strategic dynamic that will influence how the company positions each asset by patient subtype, dosing convenience, or administration route.

Efgartigimod, developed by argenx and approved by the FDA for generalised MG, represents the leading FcRn antagonist in the space. Its approval was based on clinical evidence demonstrating reduction in pathogenic autoantibody titres and improvement in MG-ADL scores. The competitive pressure efgartigimod exerts on C5 inhibitors is significant: its broader serological applicability means it can be used in patients regardless of AChR or MuSK antibody status, potentially capturing a larger eligible patient population than complement-targeted agents.

Late-Stage Clinical Development and What It Signals

Gefurulimab’s advancement into Phase II/III clinical trials in myasthenia gravis signals AstraZeneca’s strategic intent to build a next-generation complement inhibitor that can compete — or coexist — with ravulizumab in the same therapeutic space. The move into late-stage development is significant because it represents a substantial resource commitment and a bet on mechanistic differentiation within the C5 complement inhibitor class.

Phase II/III trial design in MG typically requires careful patient stratification by serological subtype — anti-AChR versus anti-MuSK — because the mechanistic rationale for complement inhibition is substantially stronger in anti-AChR patients. Regulatory agencies including the European Medicines Agency (EMA) have increasingly scrutinised patient selection criteria in rare autoimmune disease trials, and the precedent set by eculizumab’s MG approval — which was specifically in anti-AChR seropositive patients — is likely to shape the trial design and labelling strategy for gefurulimab.

The clinical development of gefurulimab also raises questions about intra-portfolio competition at AstraZeneca. With ravulizumab already approved and generating revenue in MG, the company must articulate a clear differentiation story for gefurulimab — whether through superior dosing convenience, a distinct administration modality, improved safety profile, or activity in patient subgroups where ravulizumab has shown limitations. This differentiation challenge is not unique to AstraZeneca: it mirrors the strategic dynamics seen when ravulizumab itself was developed to supersede eculizumab, with extended half-life and reduced infusion frequency as the primary differentiating attributes.

From a broader clinical perspective, the entry of gefurulimab into Phase II/III also reflects the maturation of the MG drug development ecosystem. According to data tracked by ClinicalTrials.gov, the number of interventional MG trials has grown substantially over the past decade, reflecting both increased mechanistic understanding of the disease and commercial interest driven by the orphan drug designation and premium pricing that rare autoimmune conditions typically command.

IP and Innovation Intelligence in a Rapidly Evolving Therapeutic Area

The IP landscape for complement inhibitors and FcRn antagonists in myasthenia gravis is a critical dimension of competitive analysis — and one where patent intelligence tools can provide material advantages to R&D teams, business development professionals, and IP counsel navigating this space.

In a therapeutic area where multiple agents share the same molecular target (C5 complement protein for gefurulimab and ravulizumab), the differentiation between competing IP estates typically rests on formulation patents, method-of-use claims covering specific patient populations or dosing regimens, manufacturing process patents, and combination therapy claims. The expiry profile of foundational eculizumab patents — which cover the core C5 complement inhibitor mechanism — has direct implications for the freedom-to-operate analysis that any new C5 inhibitor programme must conduct. Alexion’s eculizumab patent portfolio has been the subject of significant litigation and biosimilar challenges, and the lessons from that landscape are directly relevant to understanding the IP risks and opportunities facing gefurulimab.

For FcRn antagonists, the IP landscape is similarly contested. argenx’s efgartigimod is protected by patents covering the Fc fragment engineering that enables FcRn binding, as well as method-of-use patents for MG and other IgG-mediated autoimmune diseases. Competitors entering the FcRn space — including rozanolixizumab (UCB) and batoclimab (Immunovant) — have had to navigate around argenx’s core IP or develop sufficiently differentiated molecular architectures to establish independent patent positions.

Patent intelligence in this space requires systematic monitoring of assignee filings across major jurisdictions — US, EP, WO, CN, JP — as well as tracking of continuation applications, divisional filings, and inter partes review (IPR) proceedings that can reshape the enforceability of foundational patents. The WIPO Global Patent Index and national patent office databases provide the raw data, but the analytical layer — identifying freedom-to-operate gaps, mapping assignee strategies, and flagging emerging claim territories — requires dedicated innovation intelligence capabilities of the kind offered by platforms such as PatSnap’s core patent analytics platform.

For R&D and IP teams tracking the gefurulimab programme specifically, the key patent intelligence questions include: what claim scope does AstraZeneca assert for gefurulimab’s molecular structure and binding mechanism relative to ravulizumab; what method-of-use claims are filed for MG specifically versus broader complement-mediated conditions; and what is the anticipated expiry timeline for core composition-of-matter patents that would govern generic or biosimilar entry. These questions are answerable through systematic patent landscape analysis — and the answers will materially shape the commercial trajectory of gefurulimab relative to its competitors. For teams seeking to conduct this analysis at scale, PatSnap Insights regularly publishes deep-dive patent landscape analyses across therapeutic areas including rare autoimmune diseases.